Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5VT66
UPID:
MARC1_HUMAN
Alternative names:
Molybdenum cofactor sulfurase C-terminal domain-containing protein 1
Alternative UPACC:
Q5VT66; A8K447; B2D078; Q5VVS9; Q5VVT0; Q5VVT1; Q8N9P5; Q96FN8; Q9H6C7
Background:
Mitochondrial amidoxime-reducing component 1, also known as Molybdenum cofactor sulfurase C-terminal domain-containing protein 1, plays a crucial role in metabolic processes. It catalyzes the reduction of N-oxygenated molecules, acting as a counterpart to cytochrome P450 and flavin-containing monooxygenases. This protein is pivotal in the prodrug-converting system, enhancing drug bioavailability by reducing N-hydroxylated prodrugs, especially amidoximes.
Therapeutic significance:
Understanding the role of Mitochondrial amidoxime-reducing component 1 could open doors to potential therapeutic strategies.